Regenerative medicine remains a hot topic among spine and orthopedic surgeons. From stem cell treatments to bone grafts, biologic technology is growing, and many surgeons are optimistic.
Biologics
The regenerative medicine market is expected to hit $172.15 billion by 2030, according to market research from Next Move Strategy Consulting.
Here are seven updates in orthopedic biologics in the last 90 days:
A new clinic in Honolulu focuses on non-surgical treatments for orthopedic injuries.
One month after Bioventus announced its plan to acquire spine devicemaker Misonix in a $518 million deal, the orthobiologics company is lining up a reported $500 million purchase of Israeli medtech company Cartiheal.
Advertisement
Ortho Regenerative Technologies has extended its clinical hold on its Ortho-R drug, according to an Aug. 20 news release.
The co-founders of the Stem Cell Institute of America are being sued, accused of marketing stem cell therapy to seniors by falsely claiming that it is an effective treatment for orthopedic conditions such as arthritis and joint pain.
Bioventus has entered an agreement to acquire Misonix for $518 million in a cash-and-stock transaction.
Implant manufacturer Orthofix has launched FiberFUSE Strip, a demineralized bone graft intended to promote bone growth after spine surgery, in the U.S.
Ortho Regenerative Technologies has submitted requested data related to its Ortho-R drug to the FDA after the company paused its clinical trial.